Villarnovo Dania, McCleary-Wheeler Angela L, Richards Kristy L
aDepartment of Biomedical Sciences bDepartment of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca cSandra and Edward Meyer Cancer Center dDivision of Hematology/Oncology, Weill Cornell Medicine, New York, New York, USA.
Curr Opin Hematol. 2017 Jul;24(4):359-366. doi: 10.1097/MOH.0000000000000357.
Spontaneous lymphoma in pet dogs is increasingly recognized as an ideal model for studying the disease in humans and for developing new targeted therapeutics for patients. Increasing interest by funding agencies, the private sector, and multidisciplinary academic collaborations between different disciplines and sectors now enables large knowledge gaps to be addressed and provides additional proof-of-concept examples to showcase the significance of the canine model.
The current review addresses the rationale for a canine lymphoma model including the valuable role it can play in drug development, serving as a link between mouse xenograft models and human clinical trials and the infrastructure that is now in place to facilitate these studies. Research in this field has focused on filling in the gaps to make the canine lymphoma model more robust. These advances have included work on biomarkers, detection of minimal residual disease, expansion of genomic and proteomic data, and immunotherapy.
Incorporating pet dogs into the drug development pipeline can improve the efficiency and predictability of preclinical models and decrease the time and cost required for a therapeutic target to be translated into clinical benefit.
宠物狗的自发性淋巴瘤越来越被认为是研究人类该疾病以及为患者开发新的靶向治疗方法的理想模型。资助机构、私营部门以及不同学科和部门之间的多学科学术合作兴趣日增，现在能够填补巨大的知识空白，并提供更多概念验证实例，以展示犬类模型的重要性。
本综述阐述了犬淋巴瘤模型的基本原理，包括其在药物开发中可发挥的重要作用，作为小鼠异种移植模型与人类临床试验之间的桥梁，以及目前便于开展这些研究的基础设施。该领域的研究集中于填补空白，以使犬淋巴瘤模型更加完善。这些进展包括生物标志物研究、微小残留病检测、基因组和蛋白质组数据扩充以及免疫治疗。
将宠物狗纳入药物研发流程可提高临床前模型的效率和可预测性，并减少将治疗靶点转化为临床益处所需的时间和成本。
